GGrantIndex
← Leaderboards

G. Mike Makrigiorgos

Dana-Farber Cancer Institute

Google Scholar ↗PubMed ↗ORCID ↗
$8,320,443
Attributed
$9,727,244
Total exposure
16
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,727,244 · 16

By mechanism

R01$2,727,279 · 2
R33$2,636,694 · 3
R21$2,392,223 · 7
R42$1,490,022 · 1
R41$415,200 · 2
K04$65,826 · 1

Top collaborators

Others in their field

Top investigators on “Sampling”

Research focus

SamplingMutationTechnologyMalignant NeoplasmsDetectionTumorGenesCancer TherapyBloodAllelesSomatic MutationPlasmaPreventBaseLiquid SubstanceNew TechnologyMolecularMutantMolecular ProfilingMutation DetectionEarly DiagnosisOutcome ForecastNoiseFollow-Up

Grant awards (32)

Comprehensive minimal residual disease tracking in cancer$444,440
R01 · FY2025 · CA · contact PI
Comprehensive minimal residual disease tracking in cancer$463,940
R01 · FY2024 · CA · contact PI
Comprehensive minimal residual disease tracking in cancer$379,561
R01 · FY2020 · CA · contact PI
Maximum efficiency sequencing using nuclease-based mutation enrichment and digital barcodes$427,265
R33 · FY2019 · CA · contact PI
Comprehensive minimal residual disease tracking in cancer$369,574
R01 · FY2019 · CA · contact PI
Maximum efficiency sequencing using nuclease-based mutation enrichment and digital barcodes$437,244
R33 · FY2018 · CA · contact PI
Comprehensive minimal residual disease tracking in cancer$383,912
R01 · FY2018 · CA · contact PI
Mutation Enriched Targeted Re-Sequencing$716,511
R42 · FY2017 · CA
Maximum efficiency sequencing using nuclease-based mutation enrichment and digital barcodes$456,746
R33 · FY2017 · CA · contact PI
Mutation Enriched Targeted Re-Sequencing$773,511
R42 · FY2016 · CA
Prognostic potential of low-level mutations in meylodysplastic syndrome$228,375
R21 · FY2015 · CA · contact PI
High Z Oraya Therapy for wet AMD$215,200
R41 · FY2014 · EY
Prognostic potential of low-level mutations in meylodysplastic syndrome$190,313
R21 · FY2014 · CA · contact PI
Temperature-Tolerant COLD-PCR enables mutation-enriched targeted re-sequencing$200,000
R41 · FY2013 · CA
High-throughput technology that enables sequencing depth for colorectal CA$109,937
R21 · FY2012 · CA · contact PI
Technology for sensitive and reliable mutational profiling in pancreatic cancer$256,242
R21 · FY2011 · CA · contact PI
High-throughput technology that enables sequencing depth for colorectal CA$131,001
R21 · FY2011 · CA · contact PI
Technology for sensitive and reliable mutational profiling in pancreatic cancer$267,960
R21 · FY2010 · CA · contact PI
Technology for sensitive and reliable mutational profiling in pancreatic cancer$227,040
R21 · FY2009 · CA · contact PI
GENOME AMPLIFICATION TOLERANT TO SAMPLE DEGRADATION$327,932
R33 · FY2008 · CA · contact PI
GENOME AMPLIFICATION TOLERANT TO SAMPLE DEGRADATION$327,932
R33 · FY2007 · CA · contact PI
CIRCULATING DNA AMPLIFICATION & COLON CA DETECTION$158,182
R21 · FY2007 · CA · contact PI
CIRCULATING DNA AMPLIFICATION & COLON CA DETECTION$194,950
R21 · FY2006 · CA · contact PI
GENOME AMPLIFICATION TOLERANT TO SAMPLE DEGRADATION$143,534
R21 · FY2006 · CA · contact PI
GENOME AMPLIFICATION TOLERANT TO SAMPLE DEGRADATION$146,200
R21 · FY2005 · CA
ERROR-FREE DNA AMPLIFICATION FOR MUTATION DETECTION$170,610
R21 · FY2003 · CA
Microsphere Array for Lung Cancer Mutation Scanning$348,083
R01 · FY2002 · CA
TECHNOLOGY FOR MUTATION ANALYSIS OF CANCER$329,638
R33 · FY2002 · CA
Microsphere Array for Lung Cancer Mutation Scanning$337,769
R01 · FY2001 · CA
TECHNOLOGY FOR MUTATION ANALYSIS OF CANCER$329,937
R33 · FY2001 · CA
TECHNOLOGY FOR MUTATION ANALYSIS OF CANCER$167,879
R21 · FY2000 · CA
EVALUATION OF METAL CATALYZED HO IN CHROMATIN$65,826
K04 · FY2000 · CA